Allison Jeynes-Ellis

After qualifying as an MD, Dr. Allison Jeynes spent time practicing medicine and specializing in oncology working at various NHS institutions, including The Royal Marsden, London before moving into the life sciences industry predominantly within research and development. Now with close to 30 years of experience, she has led the strategic direction of Avillion LLP as its CEO since 2014 and has a proven track record of delivering results.

Avillion LLP is a boutique Life Sciences investment firm that funds and operationalizes clinical trials for other companies. Avillion is funded by Blackstone Lifesciences and Abingworth, investing in post POC Co-Development deals from $50m to $600m taking all the clinical & regulatory risk around the approval.

Prior to Avillion, Allison held a range of senior roles, including Medical Director for Wyeth for 6 years and International Project Team Leader for many compounds in development, leading global Phase III programs through to successful US and EU filings.